Genmab A/S (Genmab A/S) Other Long-Term Liabilities : $5 Mil (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Genmab A/S Other Long-Term Liabilities?

Genmab A/S's other long-term liabilities for the quarter that ended in Dec. 2023 was $5 Mil.

Genmab A/S's quarterly other long-term liabilities increased from Jun. 2023 ($4 Mil) to Sep. 2023 ($5 Mil) and increased from Sep. 2023 ($5 Mil) to Dec. 2023 ($5 Mil).

Genmab A/S's annual other long-term liabilities declined from Dec. 2021 ($2 Mil) to Dec. 2022 ($2 Mil) but then increased from Dec. 2022 ($2 Mil) to Dec. 2023 ($5 Mil).

Genmab A/S Other Long-Term Liabilities Historical Data

The historical data trend for Genmab A/S's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab A/S Other Long-Term Liabilities Chart

Genmab A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long-Term Liabilities

Get a 7-Day Free Trial

Genmab A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Long-Term Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Genmab A/S Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Genmab A/S Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Genmab A/S's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Genmab A/S (Genmab A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab A/S (OTCPK:GNMSF) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

GMAB:USA GMAB:Mexico GMABc:UK 0MGB:UK GMAB:Denmark GE91:Germany

Address

Kalvebod Brygge 43, Copenhagen, DNK, 1560

Website

https://www.genmab.com

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered with Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.